| Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing J Lu, S Einhorn, L Venkatarangan, M Miller, DA Mann, PB Watkins, ... Toxicological Sciences 147 (1), 39-54, 2015 | 97 | 2015 |
| Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha J Lu, AD Jones, JR Harkema, RA Roth, PE Ganey Toxicological Sciences 125 (1), 126-133, 2012 | 72 | 2012 |
| Developing a physiologically-based pharmacokinetic model knowledgebase in support of provisional model construction J Lu, MR Goldsmith, CM Grulke, DT Chang, RD Brooks, JA Leonard, ... PLoS computational biology 12 (2), e1004495, 2016 | 48 | 2016 |
| miR-122 release in exosomes precedes overt tolvaptan-induced necrosis in a primary human hepatocyte micropatterned coculture model M Mosedale, JS Eaddy, OJ Trask Jr, NS Holman, KK Wolf, E LeCluyse, ... Toxicological Sciences 161 (1), 149-158, 2018 | 45 | 2018 |
| Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine X Deng, JP Luyendyk, W Zou, J Lu, E Malle, PE Ganey, RA Roth Journal of Pharmacology and Experimental Therapeutics 322 (2), 852-861, 2007 | 37 | 2007 |
| Enzymatic hydrolysis of marine proteins and hydrolysates antioxidant activity [J] J WU, H HE, J LU, X CHEN, Y ZHANG Marine Sciences 3, 015, 2005 | 35* | 2005 |
| A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans ZY Hu, J Lu, Y Zhao British journal of pharmacology 171 (11), 2778-2789, 2014 | 22 | 2014 |
| p38 Mitogen-activated protein kinase-dependent tumor necrosis factor-α-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and … X Deng, J Lu, LD Lehman-McKeeman, E Malle, DL Crandall, PE Ganey, ... Journal of Pharmacology and Experimental Therapeutics 326 (1), 144-152, 2008 | 21 | 2008 |
| Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress J Lu, K Miyakawa, RA Roth, PE Ganey Toxicological Sciences 131 (1), 164-178, 2013 | 17 | 2013 |
| Reconstructing exposures from biomarkers using exposure-pharmacokinetic modeling–A case study with carbaryl K Brown, M Phillips, C Grulke, M Yoon, B Young, R McDougall, J Leonard, ... Regulatory Toxicology and Pharmacology 73 (3), 689-698, 2015 | 11 | 2015 |
| Roles of the hemostatic system and neutrophils in liver injury from co-exposure to amiodarone and lipopolysaccharide J Lu, RA Roth, E Malle, PE Ganey Toxicological Sciences 136 (1), 51-62, 2013 | 7 | 2013 |
| A physiologically based pharmacokinetic model of amiodarone and its metabolite desethylamiodarone in rats: pooled analysis of published data JT Lu, Y Cai, F Chen, WW Jia, ZY Hu, YS Zhao European journal of drug metabolism and pharmacokinetics 41, 689-703, 2016 | 6 | 2016 |
| Evaluating the impact of uncertainties in clearance and exposure when prioritizing chemicals screened in high-throughput assays JA Leonard, A Sobel Leonard, DT Chang, S Edwards, J Lu, S Scholle, ... Environmental science & technology 50 (11), 5961-5971, 2016 | 5 | 2016 |
| Quantitative evaluation of drug-drug interaction potentials by in vivo information-guided prediction approach F Chen, ZY Hu, WW Jia, JT Lu, YS Zhao Current Drug Metabolism 15 (8), 761-766, 2014 | 4 | 2014 |
| Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval … J Lu, J Li, G Helmlinger, N Al-Huniti Journal of Pharmacokinetics and Pharmacodynamics 45, 469-482, 2018 | 3 | 2018 |
| PERFORMANCEOF SEQUENTIAL AND SIMULTANEOUS PK/PD MODELING OF QT INTERVALS WITH PHASE I STUDIES TO PREDICT THOROUGH QT STUDY OUTCOMES. J Lu, N Al-Huniti, G Helmlinger, J Li CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S18-S19, 2018 | | 2018 |
| EXPOSURE-QT PROLONGATION ASSESSMENT USING LINEAR MIXED-EFFECTS VS. LINEAR QUANTILE MIXED-EFFECTS MODELING OF PHASE I STUDY DATA. J Lu, N Al-Huniti, E Masson, G Helmlinger, J Li CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S19-S19, 2018 | | 2018 |
| Exploration of factors impacting covariate identification in concurrent population pharmacokinetic (PopPK) modelling for parent and metabolite concentrations J Lu, D Zhou, H Xu, H Edlund, N Al-Huniti, J Li JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S61-S62, 2017 | | 2017 |
| Evaluation of computational platforms, model structures, and 90% confidence interval (CI) estimation methods in the linear mixed-effects modeling of drug concentration vs … J Lu, N Al-Huniti, E Masson, G Helmlinger, J Li JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S133-S134, 2017 | | 2017 |
| POWER OF QUADRATIC APPROXIMATION TO MODEL NONLINEAR RELATIONSHIP BETWEEN DRUG CONCENTRATION AND CHANGE FROM BASELINE IN QTC (C-Delta QTC). J Lu, N Al-Huniti, J Li CLINICAL PHARMACOLOGY & THERAPEUTICS 101 (S 1), S75-S76, 2017 | | 2017 |
